Open registration: biologics regulatory strategy and CMC, with Audrey Jia, October 24
Episode 4 of NAPPA Healthcare & Biopharma Insights takes the reviewer's view of biological products development — regulatory path and CMC.
NAPPA’s thought-leadership webinar series — NAPPA Healthcare & Biopharma Insights — continues on Saturday, October 24, 2026, 8:30–9:30 PM ET with Episode 4: Biological Products Development from Regulatory and CMC Perspective.
The episode is led by Dr. Audrey Jia, Chief Executive Officer of Wonderfulland and a former FDA reviewer. Having assessed biologics submissions from inside the agency, she now builds the programs that have to satisfy them — a vantage point on regulatory strategy that is difficult to get any other way.
What’s covered
- Regulatory strategy for biological products
- CMC considerations through the development lifecycle
- How a biologics submission reads from the reviewer’s side
- Practical perspective from former FDA review experience
Register
Registration is free for NAPPA members and qualified industry guests. Seats are limited; join details are sent by email after registering.